



**Universiteit  
Leiden**  
The Netherlands

## **Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents**

Hagemans, I.M.; Wierstra, P.J.; Steuten, K.; Molkenboer-Kuenen, J.D.M.; Dalen, D. van; Beest, M. ter; ... ; Verdoes, M.

### **Citation**

Hagemans, I. M., Wierstra, P. J., Steuten, K., Molkenboer-Kuenen, J. D. M., Dalen, D. van, Beest, M. ter, ... Verdoes, M. (2022). Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents, 20.  
doi:10.1186/s12951-022-01306-y

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3731135>


**Note:** To cite this publication please use the final published version (if applicable).

CORRECTION

Open Access



# Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris

Iris M. Hagemans<sup>1,2†</sup>, Peter J. Wierstra<sup>3†</sup>, Kas Steuten<sup>1,2</sup>, Janneke D. M. Molkenboer-Kuennen<sup>3</sup>, Duco van Dalen<sup>1,2</sup>, Martin ter Beest<sup>1</sup>, Johan M. S. van der Schoot<sup>1</sup>, Olga Ilina<sup>1,2</sup>, Martin Gotthardt<sup>3</sup>, Carl G. Figdor<sup>1,2,4</sup>, Ferenc A. Scheeren<sup>5</sup>, Sandra Heskamp<sup>3\*†</sup>  and Martijn Verdoes<sup>1,2\*†</sup>

**Correction to: Journal of Nanobiotechnology (2022) 20:64**  
<https://doi.org/10.1186/s12951-022-01272-5>

Following publication of the original article [1], the authors identified an error in Fig. 1 and Fig. 4. The correct figures are given in this correction article.

The error was in the “R-groups” (R1 and R2) of the molecules IH18 and IH20 in Fig. 1b and in Additional file 1: Figure S1. R1 and R2 were accidentally swapped. In Fig. 4d

the error was in the depiction of the tumor/blood ratio. During transfer of the data to this bar graph the data got unintentionally transformed.

---

The original article can be found online at <https://doi.org/10.1186/s12951-022-01272-5>.

---

<sup>†</sup>Iris M. Hagemans and Peter J. Wierstra contributed equally to this study. Sandra Heskamp and Martijn Verdoes contributed equally to this study

---

The original article has been revised.

---

\*Correspondence: Sandra.Heskamp@Radboudumc.nl; Martijn.Verdoes@Radboudumc.nl

---


<sup>1</sup> Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands


<sup>3</sup> Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12951-022-01306-y>.

**Additional file 1.** Supplementary figures and tables.

### Author details

<sup>1</sup>Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>2</sup>Institute for Chemical Immunology, Nijmegen, The Netherlands. <sup>3</sup>Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>4</sup>Division of Immunotherapy, Oncode Institute, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>5</sup>Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.

### Reference

- Hagemans M, Wierstra PJ, Steuten K, MolkenboerKuenen JDM, Dalen D, Beest M, Schoot JMS, Ilina O, Gotthardt M, Figdor CG, Scheeren FA, Heskamp S, Verdoes M. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris. *J Nanobiotechnol.* 2022;20:64. <https://doi.org/10.1186/s12951-022-01272-5>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.